Oppenheimer is out with its report today on Stericycle SRCL, maintaining Outperform.
In its report, Oppenheimer writes, "We're reiterating our Outperform rating and $100 price target, which is based on 31x our likely conservative 2012 EPS estimate of $3.22. Stericycle currently trades at 26x our 2012 EPS estimate, which is below the company's 5-year historical average forward multiple of 28x (range of 21x-38x). The stock is down more than 8% August-to date, which compares to the broader market (S&P 500) down just one more percentage point over the same
period."
Shares of SRCL closed Wednesday at $84.41, up 0.91% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in